Home » Stocks » LMNX

Luminex Corporation (LMNX)

Stock Price: $32.52 USD -0.47 (-1.42%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $31.00 -1.52 (-4.67%) Feb 26, 6:25 PM
Market Cap 1.51B
Revenue (ttm) 417.40M
Net Income (ttm) 14.87M
Shares Out 45.10M
EPS (ttm) 0.33
PE Ratio 100.06
Forward PE n/a
Dividend $0.37
Dividend Yield 1.14%
Trading Day February 26
Last Price $32.52
Previous Close $32.99
Change ($) -0.47
Change (%) -1.42%
Day's Open 32.58
Day's Range 30.88 - 32.90
Day's Volume 1,022,332
52-Week Range 20.53 - 41.37

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 2 weeks ago

Luminex (LMNX) witnesses total sample-to-answer molecular diagnostics revenue growth in the fourth quarter.

Zacks Investment Research - 2 weeks ago

Luminex (LMNX) delivered earnings and revenue surprises of -92.86% and 0.35%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 2 weeks ago

Shares of Luminex (NASDAQ:LMNX) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 85.71% over the past year to $0.01, which missed t...

PRNewsWire - 2 weeks ago

AUSTIN, Texas, Feb. 8, 2021 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced results for its fourth quarter and full-year ended December 31, 2020. All amounts in this release...

PRNewsWire - 2 weeks ago

AUSTIN, Texas, Feb. 8, 2021 /PRNewswire/ -- Luminex Corporation (Nasdaq:LMNX) (the "Company") today announced that its board of directors declared a cash dividend for the first quarter of 2021...

PRNewsWire - 1 month ago

AUSTIN, Texas, Jan. 13, 2021 /PRNewswire/ -- As previously announced, Luminex Corporation (Nasdaq: LMNX) will present at the 39th Annual J.P. Morgan Healthcare Conference, to be held virtually...

PRNewsWire - 1 month ago

AUSTIN, Texas, Jan. 12, 2021 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced 4th quarter 2020 revenue of approximately $111M, up approximately 23% over the 4th quarter of 20...

PRNewsWire - 2 months ago

AUSTIN, Texas, Dec. 16, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced that Nachum "Homi" Shamir, Chairman, CEO and President, and Harriss Currie, Senior Vice Presiden...

PRNewsWire - 2 months ago

AUSTIN, Texas, Dec. 7, 2020 /PRNewswire/ -- On December 3, 2020, Luminex Corporation (Nasdaq:LMNX) (the "Company"), announced that its board of directors approved a $0.01 increase in the quart...

Zacks Investment Research - 2 months ago

Luminex (LMNX) reported earnings 30 days ago. What's next for the stock?

CNBC Television - 2 months ago

These are the stocks seeing the most insider buying this week

Brian Sullivan on the top companies this week whose executives are purchasing their own stock, on Worldwide Exchange.

Other stocks mentioned: AMRN, BIIB, KDP
Zacks Investment Research - 3 months ago

Luminex (LMNX) witnessed total sample-to-answer molecular diagnostics revenue growth in the third quarter.

Seeking Alpha - 3 months ago

Luminex Corporation's (LMNX) CEO Homi Shamir on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 4 months ago

Luminex (LMNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 4 months ago

AUSTIN, Texas, Oct. 22, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it plans to report results for the third quarter ended September 30, 2020 on Thursday, Nove...

PRNewsWire - 4 months ago

AUSTIN, Texas, Oct. 7, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced 3rd quarter 2020 revenues of approximately $106 million, up approximately 35% over the 3rd quarte...

The Motley Fool - 4 months ago

You know what they say! To the most sensitive tests go the spoils.

Other stocks mentioned: BDX, FLDM, HOLX, LLY, PKI, QDEL, QGEN
Zacks Investment Research - 5 months ago

Investor confidence is high on Luminex (LMNX) stock, thanks to solid prospects.

PRNewsWire - 5 months ago

AUSTIN, Texas, Sept. 24, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received a $5,389,813 award from the Biomedical Advanced Research and Development A...

PRNewsWire - 5 months ago

AUSTIN, Texas, Sept. 23, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received an award of $683,500 from the Biomedical Advanced Research and Development...

PRNewsWire - 5 months ago

AUSTIN, Texas, Sept. 15, 2020 /PRNewswire/ -- On September 10, 2020, Luminex Corporation (Nasdaq:LMNX) (the "Company"), announced that its board of directors declared a cash dividend for the t...

Zacks Investment Research - 5 months ago

Luminex (LMNX) reported earnings 30 days ago. What's next for the stock?

The Motley Fool - 6 months ago

Blame it on Abbott.

Other stocks mentioned: CODX, GNMK, OPK
Zacks Investment Research - 6 months ago

Luminex (LMNX) witnessed total sample-to-answer molecular diagnostics revenue growth in Q2

Seeking Alpha - 6 months ago

Luminex Corporation (LMNX) CEO Nachum Shamir on Q2 2020 Results- Earnings Call Transcript

Zacks Investment Research - 6 months ago

Luminex (LMNX) delivered earnings and revenue surprises of 237.50% and -0.07%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Investors Business Daily - 6 months ago

Luminex sees its Relative Strength Rating reach the elite 90-plus level. The post Luminex Scores Relative Strength Rating Upgrade appeared first on Investor's Business Daily.

Benzinga - 6 months ago

Shares of Luminex (NASDAQ:LMNX) moved higher by 6.77% in after-market trading after the company reported Q2 results.

PRNewsWire - 6 months ago

AUSTIN, Texas, Aug. 4, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced the retirement of its Chairman, G.

Forbes - 7 months ago

Nate Pile — the editor of growth stock advisory Nate's Notes has just released the first issue of a new advisory service focused on retirement investing, The Little River Investment Guide. The...

Other stocks mentioned: AES, APAM, BRMK, BXMT, LADR, MED, PEG, PETS, PFE, PPL, SCHW
PRNewsWire - 7 months ago

AUSTIN, Texas, July 22, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has submitted an EUA request to the FDA for a new expanded version of its NxTAG® Respira...

Zacks Investment Research - 7 months ago

Luminex (LMNX) receives EUA for its xMAP SARS-CoV-2 Multi-Antigen IgG Assay, which can be used to rapidly detect the presence of antibodies in people affected by the virus causing COVID-19.

PRNewsWire - 7 months ago

AUSTIN, Texas, July 20, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it plans to report results for the second quarter ended June 30, 2020 on Tuesday, August 4,...

Market Watch - 7 months ago

Shares of Luminex Corp. LMNX, +5.06% gained 10.8% in premarket trading on Monday after the company said its COVID-19 antibody test had received an emergency use authorization from the Food and...

PRNewsWire - 7 months ago

AUSTIN, Texas, July 20, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that the Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for ...

Zacks Investment Research - 7 months ago

Luminex (LMNX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

PRNewsWire - 7 months ago

AUSTIN, Texas, July 8, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced 2nd quarter 2020 revenues of between $109 and $110 million, up more than 30% over the 2nd quarter...

Zacks Investment Research - 7 months ago

Luminex (LMNX) commences rollout of new xMAP INTELLIFLEX Systems, which will expand its xMAP Technology.

PRNewsWire - 8 months ago

AUSTIN, Texas, July 1, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that the company has delivered the first of its new xMAP® INTELLIFLEX Systems to several of its L...

Zacks Investment Research - 8 months ago

Luminex (LMNX) submits an EUA request to the FDA for its first multi-antigen IgG assay.

PRNewsWire - 8 months ago

AUSTIN, Texas, June 29, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that the company has submitted an Emergency Use Authorization request to the U.S. Food and Drug ...

Zacks Investment Research - 8 months ago

These fast movers are currently witnessing a short-term pullback in price. So, this could essentially be a solid entry point for garnering better returns in the future.

Other stocks mentioned: EVBG, SAM
Zacks Investment Research - 8 months ago

Luminex (LMNX) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 9 months ago

Luminex Corporation has been struggling lately, but the selling pressure may be coming to an end soon

Zacks Investment Research - 9 months ago

Luminex (LMNX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

PRNewsWire - 9 months ago

AUSTIN, Texas, May 22, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) (the "Company"), today announced that its board of directors declared a cash dividend for the second quarter of 2...

Seeking Alpha - 9 months ago

Luminex: Stuck In Limbo

Zacks Investment Research - 9 months ago

Luminex (LMNX) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Zacks Investment Research - 9 months ago

These fast movers are witnessing a short-term pullback in price as the COVID-19 pandemic dents investors' optimism. So, this could essentially be a great entry point for garnering better returns.

Other stocks mentioned: ACIA, VIRT
The Motley Fool - 9 months ago

The company's convertible bond offering is causing shares to slide.

About LMNX

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module v... [Read more...]

Industry
Medical Instruments & Supplies
IPO Date
Mar 30, 2000
CEO
Nachum Shamir
Country
United States
Stock Exchange
NASDAQ
Ticker Symbol
LMNX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Luminex stock is "Hold." The 12-month stock price forecast is 33.50, which is an increase of 3.01% from the latest price.

Price Target
$33.50
(3.01% upside)
Analyst Consensus: Hold